Antibe Therapeutics Inc(Pre-Merger) ATBPF

Healthcare Biotechnology

Antibe Therapeutics Inc. is a clinical-stage biotechnology company. The Company is leveraging its hydrogen sulfide (H2S) platform to develop therapies to target inflammation arising from a range of medical conditions. The Company’s pipeline includes assets that seek to overcome the gastrointestinal ulcers and bleeding associated with nonsteroidal anti-inflammatory drugs (NSAIDs). Its lead drug, otenaproxesul, is in clinical development as an alternative to opioids and NSAIDs for acute pain. Its second pipeline drug, ATB-352, is being developed for a specialized pain indication. The Company also focuses on inflammatory bowel disease (IBD). Otenaproxesul combines a moiety that releases hydrogen sulfide with naproxen, a non-steroidal, anti-inflammatory drug. ATB-352 is an H2S-releasing derivative of ketoprofen, a potent NSAID commonly prescribed for acute pain. Its IBD candidates are being designed to maintain the efficacy, safety, and pharmacokinetic properties of ATB-429.

GREY:ATBPF - Post by User

Antibe Therapeutics Inc(Pre-Merger) > Analysts upgrade

<< Previous

Bullboard Posts

Next >>

Comment by crow27on Feb 11, 2021 8:20pm

167 Views

Post# 32548378

RE:RE:RE:RE:RE:Analysts upgrade

Who are the six analysts and what are their price targets? I don't put to much faith in these guys but it's better they average $16.00 between them instead of $3.00 between them, hahaha.
Stock is only trading at .55 cents before the RS and that folks is a sceaming buy.

<< Previous

Bullboard Posts

Next >>

Global Tungsten Market and Supply Security